Skip to content
BioMark Diagnostics Menu Logo
  • About Us
    • Our Mission
    • Our Teams and Advisors
    • Awards and Achievements
    • Strategic Collaborations
    • Careers
  • Our Sciences
    • Metabolomics and Biomarkers
    • Comprehensive Metabolomics Panel (CMP)
    • Liquid Biopsy SSAT1 Assay – Legacy Platform
    • Publications and Scientific Posters
  • Investors
    • Investment Highlights
    • News Releases
    • Corporate Communication
  • Contact Us
  • About Us
    • Our Mission
    • Our Teams and Advisors
    • Awards and Achievements
    • Strategic Collaborations
    • Careers
  • Our Sciences
    • Metabolomics and Biomarkers
    • Comprehensive Metabolomics Panel (CMP)
    • Liquid Biopsy SSAT1 Assay – Legacy Platform
    • Publications and Scientific Posters
  • Investors
    • Investment Highlights
    • News Releases
    • Corporate Communication
  • Contact Us
Biomark Diagnostic Solutions

(Available Soon)

Tag: tumor response

Biomark to Expand Treatment Response Trial to Advanced Lung Cancer Patient Receiving Immunotherapy

iucpq laval press release biomark diagnostics

Vancouver, British Columbia – (June 29th, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that Health Canada has approved its clinical trial application (CTA) and has granted a Letter of No Objection (NOL) for its application entitled Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a […]

biomark-diagnostics-logo-medium2

145 –10451 Shellbridge Way, Richmond, BC
Canada V6X 2W8
Tel: +1 604 370 0779
[email protected]

Company
  • About Us | BioMark Diagnostics
  • Our Sciences
  • Investors
  • Contact us
  • About Us | BioMark Diagnostics
  • Our Sciences
  • Investors
  • Contact us
Our Sciences
  • Metabolomics and Biomarkers
  • Comprehensive Metabolomics Panel
  • Liquid Biopsy SSAT1 Assay
  • Publications and Scientific Posters
  • Metabolomics and Biomarkers
  • Comprehensive Metabolomics Panel
  • Liquid Biopsy SSAT1 Assay
  • Publications and Scientific Posters
Investors
  • Investment Highlights
  • News Releases
  • Corporate Communications
  • Investment Highlights
  • News Releases
  • Corporate Communications
Policies & Notices
  • Privacy Policy
  • Cookie Notice
  • Terms of Use
  • Privacy Policy
  • Cookie Notice
  • Terms of Use

Redefining early-stage cancer detection through liquid biopsy, metabolomics, machine learning, and artificial intelligence.

© 2026 BioMark Diagnostics Inc. All Rights Reserved. 

CSE: BUX | OTCQB: BMKDF | FSE: 20B

This page contains forward-looking statements. Actual results may differ materially. BioMark Diagnostics is listed on the Canadian Securities Exchange (CSE: BUX) and OTCQB (BMKDF). Audited by MNP LLP. Legal Council Corporate: Cozen O’Connor, Legal Counsel Patent: ROBIC LLP. All figures in Canadian dollars unless stated. This does not constitute an offer to sell or solicitation to buy securities. Refer to SEDAR+ filings for full risk factors. The content on this site is for informational purposes only and does not constitute investment advice.

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}